|
LOC110806263
|
0.090 |
GeneticVariation
|
disease |
BEFREE |
The prognostic significance of TERT promoter mutations in meningioma: a systematic review and meta-analysis.
|
30506498 |
2019 |
|
LOC110806263
|
0.090 |
GeneticVariation
|
disease |
BEFREE |
TERT promoter region was found to be mutated in 4 WHO grade II and 2 WHO grade III meningiomas.
|
29808339 |
2018 |
|
LOC110806263
|
0.090 |
GeneticVariation
|
disease |
BEFREE |
Here we have analyzed a cohort of World Health Organization grades I-III meningiomas regarding the impact of TERT promoter mutations on patient prognosis and in vitro cell propagation feasibility.
|
30010853 |
2018 |
|
LOC110806263
|
0.090 |
GeneticVariation
|
disease |
BEFREE |
TERT promoter mutation in anaplastic meningiomas was rare (14%) and did not influence overall survival but was associated with a shorter recurrence-free survival in the secondary anaplastic meningioma subgroup (P = 0.02).
|
29216385 |
2018 |
|
LOC110806263
|
0.090 |
GeneticVariation
|
disease |
BEFREE |
We analyzed 93 skull base meningiomas (82 WHO grade I, 11 WHO grade II) for mutations of hot spots or the most relevant exons of AKT1, KLF4/TRAF7, SMO, PI3K, and the TERT promoter.
|
28482067 |
2017 |
|
LOC110806263
|
0.090 |
Biomarker
|
disease |
BEFREE |
To better characterize systems in which TERT mutation studies could be appropriately modeled experimentally, the TERT promoter was examined by conventional sequencing in primary brain tumor initiating cells (BTIC), two matched recurrent BTIC lines, a panel of established malignant glioma cell lines, and two meningioma cell lines.
|
26960334 |
2016 |
|
LOC110806263
|
0.090 |
Biomarker
|
disease |
BEFREE |
Consequently, we propose to incorporate the assessment of TERT promoter status in upcoming grading schemes for meningioma.
|
26668184 |
2016 |
|
LOC110806263
|
0.090 |
GeneticVariation
|
disease |
BEFREE |
ARID1A and TERT promoter mutations in dedifferentiated meningioma.
|
25963524 |
2015 |
|
LOC110806263
|
0.090 |
GeneticVariation
|
disease |
BEFREE |
We found a high incidence of TERT promoter mutations in patients with meningiomas undergoing malignant histological progression (28%, n = 5/18 patients).
|
24261697 |
2014 |